Shivom Announces Token Buyback Plans

SHIVOM Announces Token Buyback Plans in Preparation for Platform Rollout in 2019
SHIVOM Announces Token Buyback Plans in Preparation for Platform Rollout in 2019

Shivom is pleased to announce its plans to buyback up to 30 million OMX tokens or approximately 5% of current circulating supply in preparation for Shivom’s beta platform release plans in 2019. Beyond simply removing some OMX from current market conditions, Shivom plans to allocate the repurchased OMX tokens exclusively for incentivizing early adopters and driving community engagement on the Shivom platform.

According to Shivom CEO Henry Ines, “the buyback program is part of a multi-prong strategy to accelerate growth of the Shivom ecosystem, onboard new users, drive community awareness and engagement and ultimately to further enhance the value of the Shivom platform and the OMX token ecosystem.”

The repurchased tokens will be utilized to provide incentives and benefits particularly to new users, who upload their existing genomic data file on to Shivom’s secure platform and for those who purchase Shivom-branded kits and services in 2019. The buyback program will commence on 01 November 2018 and is expected to conclude by 31 January 2019.

In the interim period, Shivom also plans to release its ‘alpha’ platform on a limited basis for early testing and feedback purposes. The company in parallel also continues to advance its clinical R&D and pilot projects.

Stay tuned for more exciting announcements!

For more information and latest updates please join our Telegram channel here

Exciting Changes within SHIVOM’s Management Team!

Exciting Changes within SHIVOM’s Management Team
Exciting Changes within SHIVOM’s Management Team

Here at OMIX Ventures Pvt Ltd. Project SHIVOM (Token Ticker: OMX), now post-ICO and focused on execution and growth, the leadership team has decided to make some significant management changes to ensure efficient execution and platform roll out.

We’re thrilled to announce that Henry Ines has been named as Chief Executive Officer of the global blockchain-based genomics and precision medicine services company.

Henry has deep experience and knowledge of strategic development, corporate finance, startup scaling and execution based on decades of professional experience to include years as a VC, while working in Silicon Valley and Asia as a partner at Draper Dragon Fund, DFJ Dragon Fund and DragonVenture and focusing on early stage investments in frontier technologies to include FinTech & blockchain, artificial intelligence and VR/AR. Henry continues to serve on the advisory board of multiple Blockchain and Silicon Valley tech startups and serves as a mentor to leading incubators and accelerators. Henry is also a lecturer at the Nanyang Technopreneurship Center (NTC), Nanyang Technological University (NTU) and is a Senior Member of the World Education Blockchain Association (WEBA) in Singapore. He began his career at McNeil Consumer Products Company, a subsidiary of Johnson & Johnson, and as a management consultant to Fortune 100 companies while working at Price Waterhouse LLP. Henry holds a BS in Finance from Pennsylvania State University in University Park, PA and an MBA from Duke University Fuqua School of Business in Durham, NC.

“As we enter the Post-ICO phase, I am thrilled to lead the team at SHIVOM, focusing on tackling the many problems associated with the global healthcare system through genomics. The current healthcare system continues to be inefficient and face considerable challenges. Patients’ data continues to not be secure as is evident with the recent disclosures of data breaches. Additionally, many of the prevailing genetics companies and healthcare intermediaries continue to advance business models and practices that are not necessarily consistent with and in the best interests of donors or patients. We are looking forward to being able to empower individuals by providing significant insights into their genomes and health, tools for better managing and determining who has access to personal healthcare data, and enabling individuals to better manage their health and wellness through SHIVOM’s secure blockchain-based technology platform and healthcare ecosystem.”

Dr. Axel Schumacher, company co-founder who has been CEO up to now will continue as Chief Scientific Officer, leveraging his extensive research background and expertise in genomics and precision medicine. Additionally, Dr. Natalie Pankova moves into the role of Chief Operating Officer, and will lead operations out of our London office, leveraging her background in startup operations, business development and R&D, as well as her deep involvement in the global healthcare blockchain community. We believe these roles reflect the most direct path to success for our company, our supporters, and our vision.

SHIVOM cannot wait to build the world’s largest genomics datahub to help support clinical trials, advance research and development and drug discovery process globally, and ultimately work to democratize genomics for all. It is our mission to not only maintain a secure and safe platform for our users and web-market players, but also address the genomic-based complex and rare diseases such as diabetes utilizing advanced technologies such as blockchain and artificial intelligence.

We have a very special team that is dedicated to SHIVOM’s mission and working hard to execute in accordance with the company’s roadmap and growth strategy. As a startup, we must be nimble, iterate as needed and quickly respond to dynamic and evolving conditions. We are confident about our new changes, and keen to work together in new capacities to more effectively execute on our vision and take the company to new heights.

Thank you for your continued support as we enter this new wave of development, and stay tuned into our media outlets for more exciting news coming soon!

Shivom Management Team

Genomic Data Hub Shivom Voted in as ICOS Project

Genomic Data Hub Shivom Voted in as ICOS Project

Shivom has been overwhelmingly voted for as a new project to receive ICOBox tools through the company’s ICOS platform.

This platform allows the ICOS token holder community to vote for what it considers to be the most promising ideas, and Shivom has received the most votes since the platform launched earlier this year. ICOBox then provides its readymade ICO solutions to the winners without an upfront payment, in exchange for their future tokens.
Shivom stands out as an innovative application of blockchain technology, applying it to work in conjunction with another promising technology, genomics. Genomic medicine shows promise to enhance the understanding and treatment of as many as 7,000 rare diseases. The ecosystem will have wide-ranging and potentially transformative uses with global application.

The core idea behind Shivom is that each individual’s DNA is a valuable and proprietary piece of information and that individuals should own this data and be able to decide how it is used and who gets to use it, and furthermore, be paid for its use as well.

As Shivom’s Gourish Singla, COO, describes, “When we submit our DNA for genetic analysis, our personal information is often sold by the laboratory to third-party companies, research institutions and nonprofits. Shivom upholds the right of every individual to their own data, and the right to sell it, but only if they wish to. Every user will have full, fine-grained control over who can see or access their genome data. In addition, to gain the volume of information necessary to study specific diseases, our company intends to recruit patients by giving the test away for free.”

To this end, the company plans to use blockchain technology, the same technology underlying Bitcoin and other cryptocurrencies, to create an ecosystem with the world’s largest database of individual DNA sequences.

A non-profit Shivom Foundation will be established to provide governance to oversee the database and give technical advice, offer marketing services and educational outreach, create incentives for contributors to share their data, and establish policies on transparency and conduct.

Embedded in our genetic code are multiple types of sensitive data that could be compromising if held in the wrong hands. As such, the Shivom database will use technologies such as state-of-the-art cryptography to ensure privacy, security and transparency, whilst blockchain will ensure the integrity of data and a decentralized approach to its storage. Using blockchain technology there is currently no viable way to hack it, or at the very least much less so when compared with traditional database systems.

The Shivom project is led by CEO Dr. Axel Schumacher, who combines 20 years of experience in the field of genetics alongside an authoritative position at the intersection of healthcare and blockchain. He is joined by an impressive cast of genomics and fintech luminaries including COO Gourish Singla, business leader and social entrepreneur; CMO Sally Eaves, Forbes Tech Council and Professor of FinTech, and CSO Per Lind, co-founder of the IOTA Foundation.

An important part of realizing this far-reaching vision will be the conduct of an ICO beginning January 10, 2018 and continuing until February 10, 2018. Shivom expects to collect a significant amount of funds in the ICO, which will help it to develop data-intensive techniques, including machine learning and artificial intelligence, to make optimal use and derive maximum benefits from the dataset.

To achieve this ambitious goal, Shivom will be using the technology and marketing tools developed by ICOBox to distribute its OmiX tokens, which will be created in the amount of 3 billion, equivalent to the number of base pairs in a haploid human genome. One third of these, approximately 990 million tokens, will be distributed in the ICO. These will be functional utility tokens that can be used in the Shivom ecosystem. for more info visit our website-


The Shivom Vision — Transforming the Future of Healthcare

We’re thrilled to announce the launch of the Project Shivom.

Over the last few years genomics and blockchain have reached the potential to significantly improve global healthcare. Genomic medicine has huge implications for the understanding and treatment of as many as 7,000 rare diseases, as well as cancers, complex disease such as cardiovascular and neurodegenerative, and infections. Project Shivom is the next evolutionary step in this development by creating a medical genomics ecosystem on the blockchain. For the first time ever, an ecosystem will offer an open web-marketplace for other providers to add not only genomics information, but also analytics, and associated apps and services to drive personalised medicine. We further aim to extend our services to form a global network of associated laboratories and research centres, as well as genetic counselors and other relevant services. On top of this global ecosystem we will build a not-for-profit R&D organization to serve the underserved, and deliver genomics sequencing technology and targeted health care. Leveraging blockchain technology, the research institute will be based on collaboration and open-innovation, that optimally connects patients, clinicians, researchers, insurers and clinical laboratories to one another. The Shivom platform works on principles of collaboration, openness, and integrity allowing patients to own their genomic data, have full access to it, and monetize it on the blockchain.

Blockchain technology is ideally suited to address most trust issues, such as patient consent, unclear data ownership, data integrity, or user authentication, enabling complex data rights management and fine-grained access using smart contracts. Using state-of-the-art blockchain technology means access to improved data security, easier data sharing, increased patient engagement, better quality ‘big data’ analytics, enhanced R&D processes, and artificial intelligence-based diagnostics for all participants. Our vision is for Shivom to be the largest genomic data-hub on the planet. In doing so, this new massive ecosystem will create value for individuals, not-for-profit organizations, governments, and for-profit entities.

We strongly believe that Shivom will change the fields of genomics, health care, and personalized medicine, for those in remote communities, and for the global system. We urge feedback on our project and whitepaper, and are excited to share further development news with you as it becomes available.